HR and breast carcinoma: Mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene are present in approximately 40% of patients with HR+/HER2- breast cancer and are correlated with poor prognosis in advanced stages of the disease (91).